PL3665196T3 - Leczenie obinutuzumabem podgrupy pacjentów z dlbcl - Google Patents

Leczenie obinutuzumabem podgrupy pacjentów z dlbcl

Info

Publication number
PL3665196T3
PL3665196T3 PL18755421.7T PL18755421T PL3665196T3 PL 3665196 T3 PL3665196 T3 PL 3665196T3 PL 18755421 T PL18755421 T PL 18755421T PL 3665196 T3 PL3665196 T3 PL 3665196T3
Authority
PL
Poland
Prior art keywords
patient subgroup
dlbcl patient
obinutuzumab
treatment
obinutuzumab treatment
Prior art date
Application number
PL18755421.7T
Other languages
English (en)
Inventor
Mikkel Zahle OESTERGAARD
Original Assignee
F. Hoffmann-La Roche Ag
Nanostring Technologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag, Nanostring Technologies, Inc. filed Critical F. Hoffmann-La Roche Ag
Publication of PL3665196T3 publication Critical patent/PL3665196T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL18755421.7T 2017-08-08 2018-08-08 Leczenie obinutuzumabem podgrupy pacjentów z dlbcl PL3665196T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762542489P 2017-08-08 2017-08-08
PCT/EP2018/071462 WO2019030260A1 (en) 2017-08-08 2018-08-08 OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP

Publications (1)

Publication Number Publication Date
PL3665196T3 true PL3665196T3 (pl) 2023-01-23

Family

ID=63209389

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18755421.7T PL3665196T3 (pl) 2017-08-08 2018-08-08 Leczenie obinutuzumabem podgrupy pacjentów z dlbcl

Country Status (19)

Country Link
US (2) US11597772B2 (pl)
EP (1) EP3665196B1 (pl)
JP (2) JP7418322B2 (pl)
KR (1) KR20200035441A (pl)
CN (1) CN111032692A (pl)
AU (1) AU2018314765A1 (pl)
CA (1) CA3071618A1 (pl)
CR (1) CR20200061A (pl)
ES (1) ES2933256T3 (pl)
IL (1) IL272418B1 (pl)
MA (1) MA49830A (pl)
MX (1) MX2020001493A (pl)
MY (1) MY202382A (pl)
PE (1) PE20200738A1 (pl)
PL (1) PL3665196T3 (pl)
SG (1) SG11202000985XA (pl)
TW (2) TW202323297A (pl)
UA (1) UA126204C2 (pl)
WO (1) WO2019030260A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202323297A (zh) 2017-08-08 2023-06-16 瑞士商赫孚孟拉羅股份公司 新穎ＤＬＢＣＬ病患次族群之歐比托珠單抗（ｏｂｉｎｕｔｕｚｕｍａｂ）治療

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870562A (en) 1986-03-20 1989-09-26 Nec Corporation Microcomputer capable of accessing internal memory at a desired variable access time
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
AU740284B2 (en) 1997-06-13 2001-11-01 Genentech Inc. Stabilized antibody formulation
DK2348051T3 (en) 2003-11-05 2019-03-18 Roche Glycart Ag CD20 antibodies with increased fc receptor binding affinity and effector function
GB0718684D0 (en) * 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
US20130195843A1 (en) * 2010-06-23 2013-08-01 British Columbia Cancer Agency Branch Biomarkers for Non-Hodgkin Lymphomas and Uses Thereof
CA2929826C (en) * 2013-11-06 2022-08-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for selecting and treating lymphoma types
DE102013222576A1 (de) 2013-11-06 2015-05-07 BSH Bosch und Siemens Hausgeräte GmbH Haushaltsgerät
MY178726A (en) 2013-11-07 2020-10-20 Hoffmann La Roche Combination therapy of an afucosylated cd20 antibody with a btk inhibitor
RU2016141385A (ru) * 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
BR112017004393A2 (pt) * 2014-09-15 2018-02-27 Genentech Inc formulações de anticorpo
RS60349B8 (sr) * 2014-09-23 2022-10-31 Hoffmann La Roche Postupak upotrebe anti-cd79b imunokonjugata
JP6979877B2 (ja) * 2015-06-08 2021-12-15 デビオファーム インターナショナル， エス． アー． 抗ｃｄ３７イムノコンジュゲートおよび抗ｃｄ２０抗体の組み合わせ
PE20181050A1 (es) 2015-06-24 2018-07-03 Hoffmann La Roche Anticuerpos contra csf-1r humano para su uso en la induccion de linfocitosis en linfomas o leucemias
CA2997406A1 (en) * 2015-12-09 2017-06-15 F. Hoffmann-La Roche Ag Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release
EP3178848A1 (en) * 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
TW202323297A (zh) 2017-08-08 2023-06-16 瑞士商赫孚孟拉羅股份公司 新穎ＤＬＢＣＬ病患次族群之歐比托珠單抗（ｏｂｉｎｕｔｕｚｕｍａｂ）治療

Also Published As

Publication number Publication date
ES2933256T3 (es) 2023-02-03
EP3665196B1 (en) 2022-10-19
TW202323297A (zh) 2023-06-16
KR20200035441A (ko) 2020-04-03
TW201910353A (zh) 2019-03-16
US11597772B2 (en) 2023-03-07
CN111032692A (zh) 2020-04-17
MX2020001493A (es) 2020-03-24
MY202382A (en) 2024-04-24
WO2019030260A1 (en) 2019-02-14
SG11202000985XA (en) 2020-02-27
IL272418B1 (en) 2024-05-01
EP3665196A1 (en) 2020-06-17
UA126204C2 (uk) 2022-08-31
MA49830A (fr) 2021-03-31
TWI772488B (zh) 2022-08-01
US20230348611A1 (en) 2023-11-02
CA3071618A1 (en) 2019-02-14
CR20200061A (es) 2020-05-23
PE20200738A1 (es) 2020-07-23
JP2023179425A (ja) 2023-12-19
AU2018314765A1 (en) 2020-01-30
JP2020530002A (ja) 2020-10-15
JP7418322B2 (ja) 2024-01-19
IL272418A (en) 2020-03-31
US20200317800A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
IL260383B (en) Low dose medication
DK3191020T3 (da) Medicinsk/kirurgisk implantat
IL262159A (en) Equipment for implanting medical devices
PL3244819T3 (pl) Urządzenie do kosmetycznego leczenia brązowych plam skóry za pomocą kriogeniki
IL250990A0 (en) Materials for human care
IL254386A0 (en) NK-3 receptor antagonists for medical or cosmetic treatment of excess body fat
HK1243657A1 (zh) 用於靶向輸送治療性植入物的裝置
DK3678714T3 (da) Vævsmanipuleret medicinsk indretning
EP3386214A4 (en) HUMAN BODY IMPLANT DEVICE
HK1249865B (zh) 疼痛的治療
SG11202001595SA (en) Angio-3 for treatment of retinal angiogenic diseases
IL261891A (en) Active retinal implant
IL272418A (en) Abinotuzumab treatment of a new subgroup of DLBCL patients
IL268187A (en) Use of Snickepok to treat stroke
GB201700526D0 (en) Therapeutic use
PL3047824T3 (pl) Urządzenie do laserowej terapii ludzkiego oka
EP3727136C0 (en) IMPLANTABLE MEDICAL DEVICE
HK1225969A1 (zh) 利用低劑量的拉喹莫德治療克隆氏病
GB201604359D0 (en) Treatment of tissue disorders
PL3501452T3 (pl) Implant medyczny
IL275150A (en) System for hypothermia treatment of a patient
PL72346Y1 (pl) Implant medyczny
HUE049399T2 (hu) Mandzsetta ortopédiai kezeléshez
GB201713975D0 (en) Medical use
PT3271015T (pt) Antagonistas do recetor nk-3 para tratamento terapêutico ou cosmético do excesso de gordura corporal